
    
      This study will evaluate the safety, efficacy and population pharmacokinetic characteristics
      of ABCD in the treatment of invasive candidiasis and invasive aspergillosis. About 60
      patients with confirmed invasive candidiasis or confirmed/probable/possible invasive
      aspergillosis will be enrolled.
    
  